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ABSTRACT
Glioblastoma (GBM) is the most lethal and aggressive adult brain tumor, 
requiring the development of efficacious therapeutics. Towards this goal, we screened 
five genetically distinct patient-derived brain-tumor initiating cell lines (BTIC) with 
a unique collection of small molecule epigenetic modulators from the Structural 
Genomics Consortium (SGC). We identified multiple hits that inhibited the growth 
of BTICs in vitro, and further evaluated the therapeutic potential of EZH2 and HDAC 
inhibitors due to the high relevance of these targets for GBM. We found that the novel 
SAM-competitive EZH2 inhibitor UNC1999 exhibited low micromolar cytotoxicity in 
vitro on a diverse collection of BTIC lines, synergized with dexamethasone (DEX) 
and suppressed tumor growth in vivo in combination with DEX. In addition, a unique 
brain-penetrant class I HDAC inhibitor exhibited cytotoxicity in vitro on a panel of 
BTIC lines and extended survival in combination with TMZ in an orthotopic BTIC model 
in vivo. Finally, a combination of EZH2 and HDAC inhibitors demonstrated synergy in 
vitro by augmenting apoptosis and increasing DNA damage. Our findings identify key 
epigenetic modulators in GBM that regulate BTIC growth and survival and highlight 
promising combination therapies.
INTRODUCTION
Glioblastoma (GBM) is the most lethal and 
aggressive adult brain tumor. The standard-of-care 
treatment includes surgical resection, followed by 
radiotherapy and chemotherapy with the alkylating 
agent temozolomide (TMZ). Despite this multifaceted 
therapy, prognosis for GBM patients remains poor with 
a median survival of only 14.6 months [1]. There are 
numerous hurdles impeding the development of successful 
GBM treatments including high inter- and intra-tumoral 
heterogeneity [2, 3], the inability of 98% known drugs 
to cross the blood-brain barrier [4] and the presence of 
a population of stem cell-like glioma cells, referred to as 
brain tumor-initiating cells (BTICs), that are thought to 
contribute to GBM propagation, treatment resistance and 
tumor recurrence [5–7]. Therefore, to further improve 
the survival of GBM patients, new therapeutic strategies 
including combination-based therapies need to be 
considered.
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Epigenetic mechanisms are being increasingly 
recognized as a major factor contributing to the 
pathogenesis of GBM [8, 9]. Epigenetic silencing of 
O-6-methylguanine-DNA methyltransferase (MGMT) by 
promoter hypermethylation is associated with significantly 
longer survival [10]. Recent genome-wide genomic and 
epigenomic analyses have revealed that 46% of 291 GBM 
samples tested have at least one somatic mutation in genes 
associated with chromatin modification [11]. Epigenetic 
alterations, particularly those involving enzymatic 
modifications of either DNA or associated histone 
proteins are currently being exploited for therapeutic 
drug targeting. However, at the moment there is limited 
knowledge regarding the mechanisms through which 
epigenetic modifiers function in GBM, and the possibility 
of therapeutic targeting has not been rigorously tested for 
this tumor.
In the current study, we performed a drug screen 
on five genetically-distinct BTIC lines with a unique 
collection of small molecule epigenetic inhibitors 
compiled by the Structural Genomics Consortium (SGC), 
and validated our findings on these and 10 additional lines. 
The BTIC lines were generated from tumors from newly 
diagnosed and recurrent GBM patients [12–17], exhibit 
the ability to self-renew and differentiate into multiple 
neural cell lineages [14], encompass the diversity of 
molecular genetic alterations that are known to occur 
in human GBM patients (e.g. EGFR, PTEN, p53, IDH1 
etc.) and are tumorigenic in orthotopic xenograft murine 
models [14, 18]. We identified multiple hits, and further 
evaluated the therapeutic potential of compounds 
regulating two epigenetic modifiers, enhancer of zeste 
homolog 2 (EZH2) and histone deacetylase (HDAC), both 
of which have high relevance for GBM.EZH2 as well as 
HDAC1 and HDAC2 are over-expressed in GBM [19–
23] and are associated with shorter overall survival [19, 
20, 22]. We show here that the SAM-competitive EZH2 
inhibitor UNC1999 exhibits low micromolar cytotoxicity 
in vitro on a diverse collection of BTIC lines, synergizes 
with Dexamethasone (DEX) and suppresses tumor growth 
in vivo in combination with DEX. Furthermore, we 
demonstrate that a unique brain-penetrant class I HDAC 
inhibitor is cytotoxic in vitro on a panel of BTIC lines 
and is able to extend survival in combination with TMZ 
in an orthotopic model in vivo. Finally, we demonstrate 
that the combination of EZH2 and HDAC inhibitors shows 
synergy in vitro by augmenting apoptosis and increasing 
DNA damage of GBM tumors.
RESULTS
Small molecule screen identifies epigenetic 
modulators that target diverse BTICs
To identify epigenetic modulators that could inhibit 
the growth of BTICs in vitro, we screened five genetically 
distinct patient-derived BTIC lines with an SGC collection 
of 24 chemical probes (Figure 1A). Compound addition 
was performed digitally using 12-point serial dilutions, 
and alamarBlue reduction was performed after 3 or 6 days 
to assess metabolic activity as an indicator of cell health. 
Compounds exhibiting IC50 values lower than 5 μM in 
either the 3 day or a 6-day screening assays were defined 
as hits (marked in red, Figure 1B). Compounds targeting 
multiple epigenetic targets were identified that suppressed 
BTIC health at low micromolar or nanomolar ranges, 
including histone methyl transferases (G9A, EZH2, 
SMYD2), BET bromodomains, histone demethylase 
(JMJD3) and histone deacetylases (HDACs). Compounds 
that targeted BET ((+)-JQ1) and JMJD3 (GSKJ4) 
have been recently described as promising compounds 
for GBM and pediatric GBM [24–26], and therefore 
we decided to not pursue them further. We tested the 
compounds targeting G9A and SMYD2 for their putative 
target inhibition (H3K9me2 and H3K4me1/H3K36me2, 
respectively) and found them inactive, suggesting that 
their cytotoxicity could be due to off-target effects. 
Therefore, we decided to focus on novel compounds 
targeting EZH2 and HDAC, both of which have high 
relevance for GBM [19–22, 27].
Targeting EZH2 in BTICs using a novel SAM-
competitive inhibitor UNC1999
EZH2 is the catalytic subunit of the Polycomb 
Repressive Complex 2 (PRC2) that inhibits gene 
expression through tri-methylation of lysine 27 on 
histone H3 (H3K27me3). Deregulation of EZH2 has 
been documented in various cancer types, both solid 
and hematological, and is associated with poor survival 
[28–30]. Therefore, we first assessed EZH2 expression in 
a panel of genetically-diverse BTIC lines. We observed 
EZH2 mRNA (Figure 2A) and protein (Figure 2B) in 
all BTIC lines tested, with virtually no expression in 
skin-derived precursor cells (SKPs), which are primary 
postnatal human neural-like dermal stem cells used as a 
normal neural stem cell control. While we did not observe 
in BTIC lines EZH2 activating point mutations Y641 
and A677 that occur in hematological malignancies, an 
increase in copy number variations (CNV) was detected 
in the majority of those lines (Supplementary Table 1).
We next compared the SAM-competitive EZH2 
inhibitors GSK126, GSK343, UNC1999 and EPZ6438 
on 10 BTIC lines for their ability to suppress cell health 
in the alamarBlue assay. UNC1999, a SAM-competitive 
EZH2/EZH1 inhibitor [31] identified in our screening of 
the SGC library, exhibited superior ability to suppress 
cell health as compared to the other inhibitors (IC50 = 2-5 
μM; Figure 2C), with EPZ6438 being inactive even at 10 
μM (data not shown). UNC2400, an inactive analogue of 
UNC1999 [29, 31], did not affect cell growth at 10 μM or 
lower, suggesting that the biological effects of UNC1999 
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were specific to its activity as a H3K27 trimethylation 
inhibitor. To address why other EZH2 inhibitors did not 
show similar efficacy to UNC1999, we compared the 
target inhibition of UNC1999 with three other EZH2 
inhibitors, GSK343, GSK126 and EPZ-6438 at the 
same concentrations (2 μM and 3 μM) on BTICs. We 
assessed different potential targets including H3K27me3, 
H3K27me2, H3K9Me2, H3K4Me1 and H3K27ac as 
well as EZH2 and total histone H3 (Supplementary 
Figure 1). UNC1999 inhibited only trimethylation of 
H3K27 without affecting the other targets or altering 
the total level of EZH2 or Histone H3. The other three 
inhibitors suppressed trimethylation of H3K27, GSK126 
and EPZ-6438 also inhibited dimethylation of H3K27, and 
GSK343 also reduced H3K9me2 and H3K4me1 levels. 
Our conclusion is that UNC1999 is more specific than the 
other inhibitors and therefore, we focused on UNC1999 
for our further studies.
Figure 1: Testing of the SGC epigenetic library of chemical probes on five BTICs lines. A. Detailed design of the screening 
procedure; B. Epigenetic screen results. Compounds that exhibit IC50 < 5 μM were defined as hits and are shown in red, drugs with 5 μM < 
IC50 < 10 μM are marked in yellow and inactive compounds that exhibit IC50 > 10 μM are shown in green.
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UNC1999 treatment of BTICs decreases cell 
viability, impairs self-renewal, causes cell cycle 
arrest and decreases H3K27Me3 levels
We first asked whether treatment of BTICs with 
UNC1999 affected cell viability. The BT73 line was 
treated with increasing concentrations of UNC1999 (4-6 
μM) and viable cells were counted at 72 and 96 hours 
post-treatment. UNC1999 significantly decreased viable 
cell numbers in a dose-dependent manner as compared 
to DMSO-treated cells at all time points tested (Figure 
3A). Next, the effect of UNC1999 on self-renewal was 
investigated. For this, BT73 and BT147 cells were treated 
with varying doses of the inhibitor and the number of 
spheres counted after 6 days. UNC1999 completely 
abrogated sphere formation at 5 μM in both BTIC 
lines (Figure 3B). To ask whether UNC1999 also had 
cytostatic effects on BTIC lines, the percentage of cells 
in the different stages of the cell cycle was examined by 
flow cytometry. BT73 cells were treated with varying 
concentrations of UNC1999 (2-5 μM), and cellular DNA 
content was examined 48 hours later. The percentage 
of cells in the G1 phase of the cell cycle significantly 
increased as a consequence of drug treatment, with a 
slight decrease in the percentage of cells in both S and 
G2/M phases (Figure 3C). In contrast, there were no 
changes in the percentage of cells at different stages of 
the cell cycle in cells treated with UNC2400, an inactive 
analogue of UNC1999 [29, 31]. In BTICs, UNC1999 
treatment completely inhibited trimethylation of lysine 27 
on Histone H3 (H3K27) without affecting the total levels 
of either Histone H3 or EZH2 (Figure 3D). Although 
there were no changes detected in the expression of the 
apoptotic marker cleaved-PARP as a consequence of drug 
treatment, we observed an increase in the expression 
of LC3B II, suggesting that the potential mechanism 
of cell death could be autophagy rather than apoptosis 
(Figure 3D), in agreement with the reported autophagic 
Figure 2: EZH2 is overexpressed in BTICs and SAM-competitive EZH2 inhibitors, in particular UNC1999, are 
cytotoxic in vitro. A. EZH2 mRNA expression in BTICs. B. EZH2 protein expression in BTICs and SKPs by immunoblotting with anti-
EZH2 antibody. C. IC50 values presented as bar graph for SAM-competitive EZH2 inhibitors using alamarBlue as a read-out.
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Figure 3: UNC1999 treatment decreases cell viability, impairs self-renewal, causes cell cycle arrest and decreases 
H3K27Me3. A. Treatment with UNC1999 (4-6 μM) reduces viable cell numbers in BT73 as assessed by trypan blue exclusion (n=3; 
** P<0.01). B. Treatment with varying concentrations of UNC1999 impairs self renewal in BT73 and BT147 as assessed by sphere 
assay (n=3). C. Treatment with UNC1999 (2-5 μM) induces G1 cell cycle arrest in BT73 as assessed by propidium iodide staining. D. 
Representative western blot demonstrates the effect of treatment with UNC1999 and the negative control UNC2400 on H3K27Me3, total 
levels of Histone H3, cleaved-PARP and LC3B in BT73 and BT147. E. Treatment with UNC1999 (5 μM) and ZVAD-FMK (20 μM) for 72 
hours does not rescue cell viability in BT73 as assessed by trypan blue exclusion (n=3; ** P<0.01). F. Treatment with UNC1999 (5 μM) and 
Necrostatin (50 μM) for 72 hours does not rescue cell viability in BT73 as assessed by trypan blue exclusion (n=3; ** P<0.01).
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mechanism of GSK343 and UNC1999-mediated cell death 
in breast and lung carcinoma cell lines [32]. In order to 
rule out apoptosis and necroptosis, we used Annexin V 
assay to assess the percentage of apoptotic cells. We could 
not detect Annexin V-positive cells at either 24, 48 or 72 
hours following UNC1999 treatment (data not shown). 
Moreover, co-incubation of cells with UNC1999 and pan-
caspase inhibitor Z-VAD-FMK did not rescue the cells 
from dying (Figure 3E), suggesting that UNC1999 induces 
cell death independently of apoptosis. Necroptosis was 
apparently not involved in UNC1999-induced cell death. 
Co-incubation of cells with Necrostatin, a necroptosis 
inhibitor [33], failed to rescue UNC1999-induced cell 
death (Figure 3F), and co-incubating the cells with 
UNC1999 and both Necrostatin and Z-VAD-FMK also did 
not have an effect on cell viability, confirming that these 
mechanisms are not compensating for each other. Since 
UNC1999 increased the expression of the autophagic 
marker LC3B II, we suggest that autophagy rather than 
necroptosis or apoptosis is the mechanism of BTIC cell 
death by this compound.
The combination of UNC1999 and 
dexamethasone is synergistic in vitro and 
suppresses tumor growth in vivo
We next asked whether UNC1999 efficacy in vitro 
can be augmented through combination with additional 
drugs. We first tested a combination of UNC1999 and 
Temozolomide (TMZ), a known GBM chemotherapeutic 
agent, on two BTIC lines (BT73 and BT147). The results 
were analyzed using the CalcuSyn median effect model, 
where the CI indicates synergysm (CI<0.9), additivity 
(CI=0.9-1.1) and antagonism (CI>1.1). We found that at 
all concentrations tested there was no synergy or additivity 
detected in a combination of UNC1999 and TMZ with 
CI values at the ED50= 2.09, ED75=1.38 and ED90=1.19 
in BT73 and ED50=1.2, ED75=1.19 and ED90=1.19 in 
BT147 (Supplementary Figure 2). We then examined a 
combination of UNC1999 with Dexamethasone (DEX), a 
corticosteroid commonly used to treat brain edema in GBM 
patients. It has been previously shown that a combination 
of a different EZH2 inhibitor, EPZ-6438, was synergistic 
with glucocorticoid receptor agonists such as prednisolone 
and dexamethasone in B cell lymphoma [34]. In agreement 
with those findings, we found that a combination of 
UNC1999 with DEX was synergistic in two different BTIC 
lines in vitro with CI values at the ED50=0.87, ED75=0.82 
and ED90=0.78 in BT73 and ED50=0.84, ED75=0.78 
and ED90=0.73 in BT147 (Figure 4A). There were no 
additional effects on H3K27me3 levels as a consequence 
of combination (Figure 4B), nor were there changes in 
EZH2 protein levels, total Histone H3 or cleaved-PARP. 
We did observe a decrease in c-MYC protein expression 
following treatment with the combination of drugs, 
although DEX alone was also able to suppress c-MYC. 
Moreover, we observed no additional increase in LC3B 
II. To investigate further potential autophagy mechanisms, 
the effect of UNC199 or DEX alone and in combination 
on p62/SQTM1, a known autophagy substrate that 
decreases as a consequence of ongoing autophagy, was 
examined. We found that in both BT73 and BT147 lines, 
p62 levels increased in the combination group as compared 
to the DMSO control and with the single drugs alone 
(Supplementary Figure 3). These findings are similar to 
other reports showing that impairment of autophagic flux 
results in autophagy-induced cell death [35, 36].
We next evaluated the efficacy of UNC1999 
treatment alone and in combination with DEX in vivo. To 
assess whether UNC1999 crossed the blood brain barrier 
and accumulated to sufficient concentrations in vivo, we 
performed a pharmacokinetic analysis of plasma and brain 
samples using LC/MS. Following oral administration of 
150 mg/kg, a dose in which UNC1999 elicited no toxicity, 
the concentration in the plasma was ~7 μM and only 0.5 
μM in the brain at both 30 min and 4 hours. Since this 
brain concentration was 10-fold less than the in vitro IC50 
on the BTIC lines, we did not proceed with an orthotopic 
model. We instead tested its efficacy in a flank xenograft 
model where we found that the concentration of the drug 
in the tumor was ~13 μM, as a proof of concept. For this 
analysis, NOD/SCID mice with small established BT73 
tumors were treated with either vehicle, UNC1999 alone 
(150 mg/kg), DEX alone (1 mg/kg) or a combination of the 
two drugs for 17 days. To evaluate target inhibition in vivo, 
we isolated tumors 10 days after initiation of treatment 
with 150 mg/kg of UNC1999. UNC1999 decreased the 
trimethylation of H3K27 in a similar fashion to that 
observed in vitro (Supplementary Figure 4), indicating that 
UNC1999 exhibits potent target inhibition both in vitro 
and in vivo. As shown in Figure 4C, UNC1999 alone was 
ineffective at suppressing tumor growth. Treatment with 
DEX alone had only a partial effect, while treatment with 
both UNC1999 and DEX significantly suppressed tumor 
growth as compared to control or single-agent treatment.
HDAC inhibitor (compound 26) treatment 
of BTICs decreases cell viability, impairs 
self-renewal, causes cell cycle arrest, induces 
apoptosis and increases acetylation of histone H3
Two class I HDAC inhibitors were identified as hits 
from the epigenetic screen, Dacinostat and CI994. Both 
HDAC1 and HDAC2 mRNA and protein were detected in 
most of the BTIC lines tested, and were absent in pediatric 
skin-derived precursor cells (SKPs) (Supplementary Figure 
5). Sequencing of BTIC lines revealed that the BT147 line 
encoded a point mutation in HDAC2, and several lines had 
an increase in HDAC2 copy number variations (CNV) 
(Supplementary Table 1). Since blood-brain-barrier (BBB) 
penetration is one of the obstacles impeding successful 
implementation of HDAC inhibitors in the clinic, we tested 
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Figure 4: UNC1999 is synergistic with dexamethasone (DEX) in vitro and suppresses tumor growth in vivo in a flank 
xenograft model. A. Representative bar graphs demonstrating synergy between UNC1999, 3.7 μM and DEX, 31 μM in vitro. B. 
Representative western blots demonstrating assessment of different targets following treatment with drugs alone and a combination in 
vitro. C. NOD/SCID mice bearing ~25 mm3 tumors were randomized into 4 groups: 1) vehicle; 2) UNC1999, 150 mg/kg, gavage; 3) DEX, 
1 mg/kg, i.p. and 4) combination. Three independent experiments were performed. Representative tumor growth data and tumor volume at 
2 weeks after treatment initiation are shown (*p<0.05; ** p<0.01).
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Figure 5: Treatment with brain-penetrant HDAC inhibitor compound 26 decreases cell viability, impairs self-renewal, 
causes cell cycle arrest, induces apoptosis and increases total levels of acetylated H3. A. Compound 26 is cytotoxic on diverse 
BTIC lines in vitro. Waterfall graph with IC50 values is shown. B. Treatment with compound 26 (100-400 nM) reduces viable cell numbers 
in BT73 as assessed by trypan blue exclusion (n=3; ** P<0.01). C. Treatment with varying concentrations of compound 26 impairs self 
renewal in BT73 and BT147 as assessed by sphere assay (n=3). D. Treatment with compound 26 (200-1000 nM) induces G1 cell cycle arrest 
in BT73 as assessed via Propidium iodide staining. E. Representative western blot demonstrates effect of treatment with compound 26 (100-
400 nM) on total acetylation of histone H3, total levels of Histone H3, HDAC1/2, p21 and cleaved PARP in BT73 and BT147. F. Treatment 
with compound 26 (400-1000 nM) increases the percentage of early and late apoptotic cells as assessed via Annexin V staining (n=3).
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an analogue of Entinostat, a known clinical HDAC inhibitor, 
optimized to improve BBB penetration in a baboon model 
[37]. This compound (referred to herein as “compound 26”) 
has been reported to inhibit recombinant human HDAC1 and 
HDAC2 at nanomolar concentrations [37]. Compound 26 
suppressed metabolic activity as determined by alamarBlue 
assay in a panel of 15 BTIC lines with IC50 values ranging 
from 57 nM to 2735 nM (Figure 5A). BT147 was identified 
as the most sensitive line, possibly due to the presence of a 
point mutation in HDAC2 which was also detected in the 
original patient tumor. Therefore, we focused our studies on 
the brain-penetrant HDAC inhibitor compound 26.
We first asked whether treatment with compound 26 
affected cell viability. BT73 cells were treated with varying 
concentrations of compound 26 (100-400 nM) and cell 
viability was determined at 72 and 96 hours post-treatment. 
The inhibitor significantly decreased cell viability in a dose 
and time-dependent manner (Figure 5B). To determine 
whether compound 26 also affected self-renewal, BT73 
and BT147 cells were treated with different doses of the 
inhibitor, and the number of spheres was quantified after 6 
days. Compound 26 completely abrogated sphere formation 
at 5 μM in both BTIC lines (Figure 5C). We next examined 
the percentage of cells found at the different stages of the cell 
cycle. BT73 cells were treated with varying concentrations 
of compound 26 (200 nM-1000 nM) and cellular DNA 
content examined 72 hours later. The percentage of cells in 
the G1 phase of the cell cycle significantly increased while 
the percentage in both S and G2/M phases was decreased 
(Figure 5D). Treatment with compound 26 induced 
hyperacetylation of Histone H3 in a dose-dependent manner, 
without affecting the total levels of Histone H3, HDAC1 or 
HDAC2 (Figure 5E). We also observed an increase in the 
levels of the cyclin-dependent kinase inhibitor p21CIP1/WAF1 
and cleaved-PARP, suggesting cell cycle arrest and apoptosis 
as potential mechanisms of action of the inhibitor (Figure 
5E). In order to further confirm the mechanism of cell 
death, we used Annexin V assay to assess the percentage 
of apoptotic cells (Figure 5F). BT73 cells were treated with 
varying concentrations of compound 26 (400 nM-1000 
nM) and the percentage of both early (Annexin V-positive, 
PI-negative) and late (Annexin V-positive, PI-positive) 
apoptotic cells was quantified 72 hours later. The percentage 
of early and late apoptotic cells significantly increased in a 
dose-dependent manner as compared to vehicle-treated cells, 
confirming that compound 26 induced cell death through 
apoptosis.
The HDAC inhibitor compound 26 crosses the 
BBB, accumulates in the brain and induces a 
significant survival benefit in vivo in combination 
with TMZ
Since compound 26 is known to cross the BBB 
in baboons, we determined the concentration that 
accumulates in mouse brain and the dose suitable for 
in vivo efficacy studies. A range of doses (3, 10, 20 and 
40 mg/kg) was administered in vivo over 5 days by oral 
gavage. Plasma and brains were collected and analyzed 
by LC/MS. Micromolar concentrations of the drug were 
detected in both the plasma and the brain (Figure 6A). 
We chose 10 mg/kg for in vivo studies, since the brain 
concentration achieved at this dose level at 3 hours was 
10-fold over the in vitro IC50 of compound 26 efficacy of 
seven BTIC lines. To determine in vivo efficacy, NOD/
SCID mice with small established BT147 intracranial 
tumors were randomized into 4 groups and treated with 1) 
vehicle, 2) compound 26 alone (10 mg/kg), 3) TMZ alone 
(50 mg/kg) or 4) combination of the two drugs for a total 
of 3 cycles (5 days ON, 2 days OFF). As shown in Figure 
6B, treatment with compound 26 alone was ineffective 
in extending survival. Treatment with TMZ alone had a 
partial effect, while treatment with both compound 26 
and TMZ was able to significantly extend survival as 
compared to control (approximately 20 days) or single-
agent treatment (by approximately 10 days).
HDAC inhibitor compound 26 is synergistic with 
UNC1999 in vitro
Lastly, we examined the efficacy of combining 
UNC1999 and the HDAC inhibitor. We hypothesized 
that inhibition of two distinct epigenetic pathways might 
complement each other and result in strong synergism. 
Indeed, a combination of UNC1999 with the HDAC 
inhibitor demonstrated strong synergism in two different 
BTIC lines in vitro with CI values at the ED50=0.55, 
ED75=0.49 and ED90=0.48 in BT73 and ED50=0.35, 
ED75 =0.30 and ED90=0.27 in BT147 (Figure 7A). 
Similarly, we observed either synergistic or additive 
effects when we tested a combination of compound 26 
and two other EZH2 inhibitors, GSK126 and EPZ6438 
(Supplementary Figure 6). For GSK126, we observed 
CI values at the ED50, ED75, ED90 of 1.04, 1.04 and 
1.05 in BT73 and ED50, ED75, ED90 of 0.78, 0.70 and 
0.64 in BT147. For EPZ6438, we detected CI values at 
the ED50, ED75, ED90 of 0.6, 0.6 and 0.61 in BT73 and 
ED50, ED75, ED90 of 0.6, 0.75 and 0.94 in BT147. These 
results suggest that simultaneously blocking EZH2 and 
HDAC1/2 may be a potential therapeutic avenue, as we 
have observed similar synergistic or additive responses 
with three structurally-different EZH2 inhibitors. We 
did not observe any additional effect on H3K27me3 
or acetylation of Histone H3 with the combination of 
compound 26 and UNC1999 (Figure 7B), nor did we 
detect changes in total levels of EZH2, Histone H3, 
HDAC1 or HDAC2. There was, however, an increase in 
cleaved-PARP, γH2AX, LC3BII as well as a decrease in 
c-MYC in cells treated with the combination of drugs, 
in particular in BT147 cells. These results suggest that 
several mechanisms are in place that can explain the 
synergy of the two compounds in vitro.
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DISCUSSION
Here we screened a unique epigenetic inhibitor 
library in order to identify candidate epigenetic modulators 
that play a role in GBM BTIC growth, survival and self-
renewal. To our knowledge, this is the first published 
report using this collection of drugs in GBM, in particular 
in primary human BTICs, which are greatly enriched in 
tumor-initiating capacity as compared to the immortalized 
cell lines [38]. Our results identify UNC1999 as a 
potent inhibitor of proliferation of human BTICs in 
vitro. UNC1999 is a novel SAM-competitive EZH2/
Figure 6: HDAC inhibitor compound 26 crosses the blood brain barrier and extends survival in an orthotopic tumor 
model in combination with TMZ. A. Pharmacokinetic results demonstrating plasma and brain concentrations in NOD/SCID mice 
treated with different doses of compound 26 over 5 days. B. NOD/SCID mice bearing intracranial tumors were randomized into 4 groups: 
1) vehicle; 2) compound 26, 10 mg/kg, gavage; 3) TMZ, 30 mg/kg, gavage and 4) combination of the 2 compounds. Kaplan-Meyer survival 
plot is shown. (* p<0.05; ** p<0.01).
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EZH1 inhibitor that has demonstrated efficacy in several 
cancer models such as leukemia, multiple myeloma and 
colon cancer [29, 39, 40]. We show here that UNC1999 
is cytotoxic in vitro in a diverse panel of GBM BTIC 
lines, inhibits self-renewal, causes cell cycle arrest at 
G1 stage and induces down-regulation of H3K27me3. 
Our data suggests that UNC1999-induced cell death is 
independent of either apoptosis or necroptosis, and may 
induce defective autophagy, as judged by the accumulation 
of both LC3BII and p62/SQSTM1. A similar mechanism 
of action has been recently described by Button et al. for 
dual PI3K/mTOR inhibitors [35].
Increased and decreased expression of EZH2 have 
both been implicated in the development and progression 
of a variety of cancers types. EZH2 overexpression is 
associated with aggressiveness and worse prognosis in 
prostate, breast, bladder, endometrial tumors, melanoma 
and GBM [30]. Additionally, gain-of-function point 
mutations at Y641 of EZH2 were identified in 22% 
of DLBCL and 7-12% of follicular lymphomas [41]. 
These mutations result in enhanced enzymatic function 
of EZH2 leading to increased levels of tri-methylated 
H3K27 and repression of PRC2 targets. However, EZH2 
can also act as a tumor suppressor, with loss-of-function 
Figure 7: HDAC inhibitor compound 26 synergizes with UNC1999 in vitro through augmented apoptosis and DNA 
damage. A. Representative bar graphs demonstrating synergy between UNC1999, 3.8 μM and compound 26, 385 nM in vitro (n=3; * 
p<0.05; ** p<0.01). B. Representative western blots demonstrating assessment of different targets following treatment with drugs alone 
and a combination in vitro.
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mutations identified in a subset of myelodisplastic 
syndromes, myeloproliferative neoplasms and T cell 
acute lymphoblastic leukemias. Moreover, recurrent 
missense mutations in the PRC2 substrate lysine residue 
27 of histone H3 and its variants occur in 31% of pediatric 
GBM, 78% of diffuse intrinsic pontine glioma (DIPG) 
and 50% of pediatric high-grade gliomas (pHGG), but 
not in adult GBM. The H3K27M mutation is oncogenic, 
blocking growth-suppressive PRC2 methylation activity 
resulting in reduced H3K27 methylation and derepression 
of PRC2 target genes. In this regard, inhibition of H3K27 
demethylation mediated by JMJD3, using the inhibitor 
GSK-J4, suppressed the growth of DIPG tumors grown as 
xenografts [24]. Thus, while EZH2 inhibition may prove 
beneficial in adult GBM, it will most likely be detrimental 
for patients with pediatric gliomas.
Until now, most of the studies in GBM have 
used either EZH2 knockdown or treatment with 
3-deazaneplanocin (DZNep) in order to assess the effect of 
EZH2 inhibition [19, 42, 43]. However, DZNep is a potent 
S-adenosylhomocysteine inhibitor which inhibits EZH2 
in an indirect manner though depletion of cellular levels 
of all PRC2 components, resulting in decreased H3K27 
methylation. In contrast, UNC1999 directly inhibits 
EZH2 and in a potent and selective manner. Interestingly, 
de Vries et al. reported that prolonged EZH2 depletion in 
glioma switched tumor cells to a different epigenetic state 
that enhanced cell proliferation and DNA damage repair, 
resulting in tumor progression [44]. However, short-
term EZH2 depletion significantly improved survival, 
suggesting that determining the precise dosing schedules 
will be crucial for a successful implementation of EZH2 
inhibitors into the clinic.
We hypothesize that the superior efficacy of 
UNC1999 in vitro as compared to other EZH2 inhibitors 
may be due to its ability to simultaneously target 
both EZH2 and EZH1. Konze et al. [31], which first 
characterized UNC1999, found that it was 10,000-
fold more selective for EZH2 as compared to other 
methyltransferases (Konze et al., Figure 2G). The only 
other histone methyl transferase that UNC1999 inhibited 
was EZH1, albeit 10-fold less potently than EZH2. In 
contrast, GSK126 and EPZ-6438 were over 50-fold more 
potent towards EZH1 than EZH2. This finding suggests 
that UNC1999 may be more effective in inducing BTIC 
cell death due to suppression of both EZH2 and EZH1.
An additional issue regarding the existing EZH2 and 
HDAC class I inhibitors is their inability to penetrate the 
blood-brain barrier (BBB) [45]. BBB penetration is one of 
the major issues impeding successful therapeutic targeting 
in GBM, as more than 98% of drugs fail to cross the BBB. 
Although UNC1999 did not cross the BBB, we report 
on the efficacy of a promising class I HDAC inhibitor, 
optimized for optimal brain penetration. This inhibitor was 
identified when a series of compounds using Entinostat 
as a backbone were synthesized and tested in baboons 
[37]. Compound 26 from these studies potently inhibited 
HDAC1 and HDAC2 and crossed the BBB. This inhibitor 
exhibited nanomolar to low micromolar cytotoxicity in 
vitro, disrupted self-renewal, caused cell cycle arrest, 
induced apoptosis and hyper-acetylation of histone H3 
and demonstrated efficacy in an orthotopic BTIC model in 
combination with TMZ. Interestingly, we have also found 
that a combination of the UNC1999 EZH2 and compound 
26 HDAC class I inhibitors demonstrated synergy in vitro. 
This combination has been previously tested in other 
cancers such as gallbladder carcinoma [46], however 




GBM BTIC lines BT50, BT53, BT67, BT73, BT75, 
BT92, BT100, BT119 BT143 and BT147 were previously 
described [14–16, 18]. BTIC lines BT69, BT140, BT161, 
BT167, BT194, BT198 and BT208 were cultured from a 
series of tumor specimens (see Supplementary Table 2) 
obtained following informed consent from adult GBM 
patients during their operative procedure as previously 
described [14] with the approval of the University of 
Calgary Ethics Review Board. Briefly, BTIC cultures were 
initiated in defined culture serum-free medium (SFM) 
and gave rise to non-adherent spheres after 7–21 days in 
culture. Primary tumor spheres were expanded for several 
passages and then cryopreserved in 10% DMSO in SFM 
until use in experiments (14). All BTIC lines were used at 
passages of approximately 10-20.
Epigenetic library
The epigenetic library consists of 24 small molecule 
compounds targeting diverse epigenetic targets. The 
library (http://www.thesgc.org/chemical-probes) was 
kindly provided by the Structural Genomics Consortium 
(SGC, Toronto, ON; http://www.thesgc.org).
Drugs
UNC1999, GSK343, EPZ6438, GSK126 and 
Necrostatin were from Selleck Chemicals, Dexamethasone 
and Temozolomide from Sigma, Z-VAD-FMK from 
Calbiochem, and UNC2400, a negative control for 
UNC1999, was kindly provided by the SGC. The brain 
penetrant HDAC inhibitor Compound 26 was obtained 
from a six step synthesis starting from 4-bromo-2-
nitroaniline based on a previously reported synthetic route 
[37]; dx.doi.org/10.1021/cn500021p).
Primary screening assay
Five BTIC lines (BT143, BT53, BT69, BT100 and 
BT194) were dissociated into single cells and seeded 
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at 1000-2500 cells/well in 50 μL medium in 384-well 
microplates. Compounds were dissolved in DMSO 
as 10 mM stocks. Compound addition was performed 
at OICR using HP Tecan D300 digital dispenser. For 
each compound, 12-point, 2-fold serial dilutions were 
performed. Drug effects were compared to cells optimally 
proliferating in 0.1% DMSO alone, while wells filled 
with media served as background. AlamarBlue® (5 μL) 
was added after 3 or 6 days, and fluorescence intensity 
measured after 6 hr on a PHERAstar microplate reader, 
equipped with a λ540 excitation/ λ590 emission filter.
Whole genome and transcriptome sequencing
DNA and RNA from each BTIC line and DNA from 
peripheral blood from the respective patients were used 
to construct genome and transcriptome libraries. Whole 
genome and transcriptome paired-end sequencing using 
the Illumina HiSeq2500 platform generated an average 
genome coverage of 40X and average transcriptome 
read counts of 200 million. Genomic sequence data 
from normal and tumor were then aligned to the human 
reference genome build GRCh37 using BWA (v0.5.7). 
Data from multiple lanes were merged and duplicates 
identified using Picard (v1.38). CNASeq (v0.0.6) and 
APOLLOH (v0.1.1) were used to identify copy number 
aberrations and loss of heterozygosity respectively. For 
identification of single nucleotide variants, Samtools 
(v1.0.2) was applied followed by filtering with 
MutationSeq (v1.0.2), and the results were combined 
with variant called with Strelka (v0.4.6.2). Small indels 
were also identified using Strelka. These variants were 
annotated using Ensembl (v69). Transcriptome reads were 
gap-aligned using the Jaguar pipeline (v2.0.3). Further in-
house tools were used to generate read counts for exons 
and genes and calculate expression levels using reads per 
kilobase per million mapped reads (RPKM).
Western blot analysis
For cell lysis, cells were collected, washed in 
cold PBS, and lysates prepared in RIPA lysis buffer. 
Equal amounts of protein were resolved on gradient 
polyacrylamide gels and subjected to immunoblotting 
with the following antibodies: rabbit anti-EZH2 (1:1000, 
CST#5246), rabbit anti-H3K27me3 (1:1000, CST#9733), 
rabbit anti-H3K27me2 (1:1000, CST#9755), rabbit anti-
H3K4me1 (1:1000, CST#5326), rabbit anti-H3K9me2 
(1:1000, CST#4658), mouse anti-H3K27ac (1:2500, 
Milllipore 17-683), rabbit anti-histoneH3 (1:1000, 
Millipore 05-928), rabbit anti-cleaved PARP (1:1000, 
CST#9541L), rabbit anti-LC3B (1:1000, CST#3868P), 
rabbit anti-cMYC (1:1000, CST#13987), rabbit anti-acetyl 
histone H3 (1:1000, Millipore 06-599), rabbit anti-p21 
(1:1000, CST#2947S), mouse anti-HDAC1 (1:1000, 
CST#5356), mouse anti-HDAC2 (1:1000, CST#5113), 
rabbit anti-SQSTM1/p62 (1:1000, CST#8025), rabbit anti-
phospho-Histone H2A. X (1:1000, Millipore 05-636), and 
rabbit anti-GAPDH (1:1000, CST#5174). HRP-conjugated 
goat anti-mouse IgG (1:5000) and goat anti-rabbit IgG 
(1:10,000) were used as the secondary antibodies.
Immunofluorescence
Cells underwent Cytospin, fixed either with 4% 
PFA (anti-SQSTM1/p62) or 100% methanol (anti-LC3B), 
permeabilized with PBS/0.2% Triton X-100, washed with 
PBS/ 100 mM Glycine and then incubated in IF buffer 
(PBS, 0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20), 
with 2% BSA for 30 minutes as a blocking solution. 
Slides with cells were incubated with primary antibodies 
in blocking solution at 4°C overnight. After washing 
with IF buffer, the cells were incubated with secondary 
antibodies in blocking solution for 1 hr at RT. Finally, after 
PBS washes, slides were mounted in Permount solution 
(Thermo, Walthman, MA). Digital image acquisition was 
performed with Axiovision software (Zeiss, Oberkochen, 
Germany) on a Zeiss Axioplan 2 microscope with a 
Hamamatsu (Bridgewater, NJ) Orca-R2 CCD video 
camera.
Drug combination studies
The combination index (CI) was used to evaluate the 
interaction between different drugs [47]. BT73 and BT147 
were dissociated into single cells, seeded at 1000-3000 
cells/well in 100 μL medium in 96-well plates and treated 
with increasing concentrations of UNC1999, HDAC 
inhibitor, DEX and TMZ. Six days after the incubation, 
alamarBlue® (10 μL) was added to the plates and 
fluorescence intensity measured after 6 hr on a PHERAstar 
microplate reader, equipped with a λ540 excitation/λ590 
emission filter. The CalcuSyn median effect model was 
used to calculate the CI values and evaluate whether 
the drug combinations were synergistic, antagonistic, 
or additive. CI values of < 1 indicate synergism, CI = 1 
indicate additivity, and CI > 1 indicate antagonism [47].
Pharmacokinetic (PK) properties and blood 
brain barrier (BBB) penetration of compounds
To obtain plasma exposure and BBB penetration 
of compounds at various time points, blood and brains 
were collected form mouse after dosing compounds at 
different time points. Plasma was separated from blood by 
centrifugation. For analysis 20 μL plasma was transferred 
into a 1.5 mL microcentrifuge tube, to which 40 μL 
acetonitrile was added to denature and precipitate proteins, 
and were centrifuged for 6.5 min. at 14000 rpm. The 
supernatant was transferred to LCMS vials for analysis.
For quantification of drug levels in brain samples, 
brains were transferred to plastic vials containing 1:2 
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(brain:water, e.g. 300 mg brain with 600 μL water) volume 
of water and 2 glass Pyrex beads (4mm in size). Samples 
were homogenized by bead beating (3 X 15 second 
pulses of 5,000 rpm) using a Precellys 24 homogenizer 
(Bertin Technologies, Montigny-le-Bretonneux, France). 
Each sample was mixed vigorously with 2 volumes of 
acetonitrile to precipitate out protein and were centrifuged 
for 6.5 min. at 14000 rpm. The supernatant was then 
transferred to LCMS vials for analysis. The concentration 
in brain was corrected for dilution.
LCMS analysis
For each analysis, a calibration curve with ten 
different concentrations starting from 10 mg/mL up to 
10,000 ng/mL was prepared by spiking blank plasma. 
Chromatographic separations were carried out on an 
Acquity UPLC BEH C18 (2.1 X 50 mm, 1.7 μm) column 
using ACQUITY UPLC II system. The mobile phase was 
0.1% formic acid in water (solvent A) and 0.1% formic 
acid in acetonitrile (solvent B). A gradient starting at 
95% solvent A going to 5% in 4.5 min., holding for 0.5 
min., going back to 95% in 0.5 min. and equilibrating the 
column for 1 min. was employed. A Waters Synapt G2S 
QTof mass spectrometer equipped with an atmospheric 
pressure ionization source was used for mass spectrometric 
analysis. MassLynx 4.1 was used for data analysis.
Determination of cellular DNA content
The BTIC line BT73 (0.2x106) was plated in 6-well 
dishes and DMSO, UNC1999 (2 μM, 3 μM and 5 μM) or 
HDAC inhibitor (0.2 μM, 0.4 μM, 0.6 μM and 1 μM) added. 
After 48 hrs (UNC1999) or 72 hrs (HDAC inhibitor), cells 
were harvested, washed with PBS and fixed in 70% ice-cold 
ethanol. Fixed cells were treated with RNAseA, stained with 
Propidium Iodide at 37°C for 1 hr and analyzed on a LSR II 
flow cytometer to determine cellular DNA content.
Viable cell counts following treatment with 
UNC1999 and HDAC inhibitor
1x105 dissociated BTICs (BT73) were seeded in 
triplicate in 12-well non-tissue culture-treated plates 
in 2 mL of medium. UNC1999 (4 μM - 6 μM), HDAC 
inhibitor (0.1 μM - 0.4 μM) or 0.1% DMSO were added to 
the cells 24 hrs later. At specific time points, spheres were 
collected, dissociated and subjected to a viable cell count 
by trypan blue exclusion.
Annexin V assay
The ability of drugs to induce apoptosis in BTICs 
was determined with an Annexin V-FITC detection kit, 
used according to the manufacturer’s instructions (BD 
Pharmingen). Briefly, 0.3x106 BTICs (BT73) were plated 
in 6-well dishes and treated with various concentrations 
of UNC1999 (3-6 μM) or HDAC inhibitor (0.4 – 1 
μM). Cells were harvested 24-72 hr later, stained for 
Annexin V/propidium iodide and analyzed on a LSR II 
flow cytometer. Relative numbers of early apoptotic cells 
(Annexin V-positive, Propidium iodide-negative) and late 
apoptotic cells (Annexin V-positive, Propidium iodide-
positive) were obtained for each time point.
Sphere-formation assay
BTICs (BT73 and BT147) were seeded in triplicate 
in non-TC-treated 96-well microplates at a density of 
1000-2500 cells/well in 50 μL/well. Compounds were 
diluted in medium (1:1000) and immediately added to the 
cells in a volume of 50 μL (final concentration of DMSO 
= 0.05%). Cells were re-treated 72 hrs post-plating with 
drugs, and fixed after 6 days with 4% paraformaldehyde 
(Electron Microscopy Sciences). Sphere number was 
determined by manual counting, and the results expressed 
as the mean sphere number of treated wells as compared 
to DMSO-treated wells*100.
Flank xenograft model
1.5x106 BTICs (73M) were resuspended in media 
and injected in 100 μl volume subcutaneously into 6-8-
week old NOD/SCID mice. Drug treatment began when 
tumor size reached ~25 mm3. Animals were randomized 
into 4 groups: 1) Vehicle; 2) UNC1999 alone; 3) DEX 
alone; 4) UNC1999 + DEX. Mice were injected via oral 
gavage with either vehicle (10% DMSO, 40% PEG) 
or UNC1999 (150 mg/kg) every day for 17 days. An 
additional group of mice received intraperitoneal injection 
of DEX (1 mg/kg) every day for 17 days. The combination 
group received both UNC1999 and DEX administered by 
oral gavage and i.p. injection respectively.
Orthotopic xenograft model
BT147 spheres were dissociated into single 
cell suspensions and 1x105 cells were stereotactically 
implanted into the right striata of 6-8 week old NOD/SCID 
mice as previously described [14]. Seven days after BTIC 
implantation, mice were randomized into 4 groups and 
injected via oral gavage for a total of 3 cycles (5 days ON, 
2 days OFF): 1) vehicle (50% PEG, 50% water); 2) HDAC 
inhibitor alone (10 mg/kg); 3) Temozolomide (TMZ) alone 
(30 mg/kg) and 4) combination of HDAC inhibitor and 
Temozolomide.
Statistical analysis
Statistical analyses were performed with Microsoft 
Excel using an unpaired, two-tailed student’s T-test with 
P<0.05 as the significance cutoff. One-way ANOVA was 
used to determine statistically significant differences from 
the mean in the combination study in vivo.
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